437 Efficacy and safety of tumor necrosis factor inhibitors in cutaneous sarcoidosis: A systematic review

Sarcoidosis is a multisystem disease of unknown etiology characterized by noncaseating granulomas that often affect the skin. Tumor necrosis factor (TNF) is essential in formation of granulomas. Growing evidence supports anti-TNF agents for refractory sarcoidosis, including infliximab (IFX), etanercept, adalimumab ( ADA ), golimumab (GOL) and certolizumab. We sought to characterize the efficacy and safety of anti-TNF in all types of sarcoidosis by performing a systematic review that included trials and case series.

Source: Journal of Investigative Dermatology - April 19, 2018 Category: Dermatology Authors: B. Adler, C. Wang, T. Bui, H. Schilperoort, A.W. Armstrong Tags: Clinical Research: Pathophysiology and Therapeutics Source Type: research